GLP1R and type 2 diabetes mellitus: This paper includes the ADA’s current recommendations for diabetes care, treatment goals and guidelines, and quality of care evaluation tools. GLP-1 receptor agonists and SGLT2 inhibitors reduce the risk of ASCVE to a comparable degree in patients with type 2 diabetes and established ASCVD.